HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.

AbstractAIMS/INTRODUCTION:
Dipeptidyl peptidase-4 inhibitors might have pleiotropic protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore, we compared various CVD risk factors between vildagliptin and glimepiride.
MATERIALS AND METHODS:
We carried out a randomized, prospective and crossover trial. A total of 16 patients with type 2 diabetes whose glycated hemoglobin was >7% were randomized to add vildagliptin or glimepiride. After 12-week treatment, each drug was replaced with the other for another 12 weeks. Before and after each treatment, glucose homeostasis and CVD risk factors were assessed, and the continuous glucose monitoring system was applied to calculate glycemic variability.
RESULTS:
The mean age of the participants was 60 years, 31% were men, body mass index 25.5 kg/m2 and HbA1c 8.41%. Both vildagliptin and glimepiride significantly decreased glycated hemoglobin and glycemic variability indices. Despite the improved glucose homeostasis, favorable change of CVD markers was not prominent in both the arms, along with significant weight gain. Only plasma stromal cell-derived factor (SDF)-1α decreased by 30% in the vildagliptin arm. According to regression analyses, the reduction of SDF-1α was independently associated with vildagliptin usage and serum interleukin-6 changes, but white blood cells were not related with the SDF-1α changes.
CONCLUSION:
Compared with glimepiride, vildagliptin arrestingly decreased plasma SDF-1α, and its clinical implications should be further investigated.
AuthorsKyeong Seon Park, SooHeon Kwak, Young Min Cho, Kyong Soo Park, Hak C Jang, Seong Yeon Kim, Hye Seung Jung
JournalJournal of diabetes investigation (J Diabetes Investig) Vol. 8 Issue 2 Pg. 218-226 (Mar 2017) ISSN: 2040-1124 [Electronic] Japan
PMID27575011 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Chemical References
  • CXCL12 protein, human
  • Chemokine CXCL12
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Nitriles
  • Pyrrolidines
  • Sulfonylurea Compounds
  • hemoglobin A1c protein, human
  • glimepiride
  • Vildagliptin
  • Adamantane
Topics
  • Adamantane (analogs & derivatives, therapeutic use)
  • Cardiovascular Diseases (blood, complications, prevention & control)
  • Chemokine CXCL12 (blood)
  • Cross-Over Studies
  • Diabetes Mellitus, Type 2 (blood, complications, drug therapy)
  • Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
  • Female
  • Glycated Hemoglobin (metabolism)
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Male
  • Middle Aged
  • Nitriles (therapeutic use)
  • Prospective Studies
  • Pyrrolidines (therapeutic use)
  • Risk Factors
  • Sulfonylurea Compounds (therapeutic use)
  • Vildagliptin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: